ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0918

Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and Without Gastroesophageal Reflux Disease: Further Analyses of the SENSCIS Trial

Kristin Highland1, Gerard Criner2, Petros Sfikakis3, Hilario Nunes4, Wendy Stevens5, Corinna Miede6, Margarida Alves7 and Michael Kreuter8, 1Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, 2Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, 3National Kapodistrian University of Athens Medical School, Athens, Greece, 4Department of Pulmonology, Hôpital Avicenne, APHP, Bobigny, France, Bobigny, France, 5Department of Rheumatology, St Vincent's Hospital, Melbourne, Victoria, Australia, Fitzroy, Victoria, Australia, 6mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, 7Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 8Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany, Heidelberg, Germany

Meeting: ACR Convergence 2020

Keywords: Comorbidity, interstitial lung disease, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Gastroesophageal reflux disease (GERD) is a common comorbidity in patients with SSc-ILD and may be associated with progression of SSc-ILD. In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks by 44% versus placebo, with an adverse event profile characterized mainly by gastrointestinal events. We investigated the efficacy and safety of nintedanib in subgroups by presence of GERD at baseline.

Methods: In the SENSCIS trial, patients with SSc-ILD with first non-Raynaud symptom ≤7 years before screening, extent of fibrotic ILD ≥10% on HRCT and FVC ≥40% predicted were randomized to receive nintedanib or placebo until the last patient had reached week 52 but for ≤100 weeks. In post-hoc analyses, we analysed the annual rate of decline in FVC (mL/year) over 52 weeks and adverse events in subgroups by presence of GERD prior to and/or at screening. GERD was defined as present if it was noted as a present or past comorbidity on the SSc-related medical history page of the case report form.

Results: Of 576 patients who received ≥1 dose of trial medication, 74.3% had GERD prior to and/or at screening. At baseline, in patients with and without GERD, respectively, mean (SD) FVC was 2532 (787) and 2405 (744) mL and 72.3 (16.7) and 73.1 (16.7) % predicted; 88.8% and 52.0% of patients were taking anti-acid therapy. In the placebo group, the adjusted annual rate of FVC decline was numerically more pronounced in patients with than without GERD (-97.3 vs -81.6 mL/year). The effect of nintedanib versus placebo on reducing the rate of FVC decline (mL/year) was numerically more pronounced in patients with than without GERD (difference: 48.2 [95% CI: 3.9, 92.5] vs 20.2 [-54.6, 95.0]), but the exploratory interaction p-value did not indicate heterogeneity in the treatment effect of nintedanib between these subgroups (p=0.53) (Figure). The most frequent adverse event reported in all the subgroups was diarrhea (Table). In the nintedanib and placebo groups, respectively, the proportions of patients who had adverse events leading to treatment discontinuation were 14.6% and 9.7% in patients with GERD and 19.7% and 5.6% in patients without GERD.

Conclusion: In the SENSCIS trial in patients with SSc-ILD, nintedanib slowed the rate of FVC decline versus placebo both in patients with and without GERD. The adverse event profile of nintedanib was similar in patients with and without GERD.


Disclosure: K. Highland, Actelion Pharmaceuticals, 1, 2, 3, Bayer, 1, 2, Boehringer Ingelheim, 1, 2, 3, Eiger BioPharmaceuticals, 1, Genentech, 1, Gilead Sciences, 1, Gossamer Bio, 1, Reata Pharmaceuticals, 1, United Therapeutics, 1, 2, 3, Viela Bio, 1; G. Criner, Amgen, 1, AstraZeneca, 1, Boehringer Ingelheim, 1, Broncus Medical, 1, CSA Medical, 1, Eolo Medical, 1, Gala Therapeutics, 1, GlaxoSmithKline, 1, HGE Health Care Solutions, 1, Helios Medical, 1, Merck, 1, Medtronic, 1, Mereo BioPharma, 1, NGM Biopharmaceuticals, 1, Novartis, 1, Olympus, 1, PulmonX, 1, Philips Respironics, 1, Respivant Sciences, 1, The Implementation Group, 1, Verona Pharma, 1; P. Sfikakis, Abbvie, 2, 5, Amgen, 2, 5, Boehringer Inglheim, 2, 5, Celgene, 2, 5, Eli Lilly, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5; H. Nunes, Boehringer Ingelheim, 1, 2, 3, Roche, 1, 2, 3, Galapagos, 1; W. Stevens, Janssen, 5, 8, Boehringer Ingelheim, 5, Actelion Pharmaceuticals, 2; C. Miede, Boehringer Ingelheim, 9; M. Alves, Boehringer Ingelheim, 3; M. Kreuter, Boehringer Ingelheim, 1, 2, Galapagos, 1, Roche, 1, 2.

To cite this abstract in AMA style:

Highland K, Criner G, Sfikakis P, Nunes H, Stevens W, Miede C, Alves M, Kreuter M. Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and Without Gastroesophageal Reflux Disease: Further Analyses of the SENSCIS Trial [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/decline-in-forced-vital-capacity-in-patients-with-systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-with-and-without-gastroesophageal-reflux-disease-further-analyses-of-the-senscis-tr/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decline-in-forced-vital-capacity-in-patients-with-systemic-sclerosis-associated-interstitial-lung-disease-ssc-ild-with-and-without-gastroesophageal-reflux-disease-further-analyses-of-the-senscis-tr/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology